Skip to main content
Erschienen in: Advances in Therapy 3/2014

01.03.2014 | Review

Zonisamide as a Treatment for Partial Epileptic Seizures: A Systematic Review

verfasst von: Joanna H. Cox, Stefano Seri, Andrea E. Cavanna

Erschienen in: Advances in Therapy | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Although the majority of people with epilepsy have a good prognosis and their seizures can be well controlled with pharmacotherapy, up to one-third of patients can develop drug-resistant epilepsy, especially those patients with partial seizures. This unmet need has driven considerable efforts over the last few decades aimed at developing and testing newer antiepileptic agents to improve seizure control. One of the most promising antiepileptic drugs of the new generation is zonisamide, a benzisoxazole derivative chemically unrelated to other anticonvulsant agents. In this article, the authors present the results of a systematic literature review summarizing the current evidence on the efficacy and tolerability of zonisamide for the treatment of partial seizures. Of particular interest within this updated review are the recent data on the use of zonisamide as monotherapy, as they might open new therapeutic avenues.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat World Health Organization. The world health report 2001—mental health: new understanding, new hope. World Health Organization; 2001. World Health Organization. The world health report 2001—mental health: new understanding, new hope. World Health Organization; 2001.
2.
Zurück zum Zitat Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–2.PubMedCrossRef Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–2.PubMedCrossRef
4.
Zurück zum Zitat Berg AT, Bercovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51:676–85.PubMedCrossRef Berg AT, Bercovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51:676–85.PubMedCrossRef
6.
Zurück zum Zitat Mitchell JW, Seri S, Cavanna AE. Pharmacotherapeutic and non-pharmacological options for refractory and difficult-to-treat seizures. J Cent Nerv Syst Dis. 2012;19:105–15. Mitchell JW, Seri S, Cavanna AE. Pharmacotherapeutic and non-pharmacological options for refractory and difficult-to-treat seizures. J Cent Nerv Syst Dis. 2012;19:105–15.
7.
Zurück zum Zitat Nunes VD, Sawyer L, Sarri G, Cross H. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281.PubMedCrossRef Nunes VD, Sawyer L, Sarri G, Cross H. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281.PubMedCrossRef
8.
9.
Zurück zum Zitat Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77.PubMedCrossRef Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77.PubMedCrossRef
10.
Zurück zum Zitat Leppik IE. Three new drugs for epilepsy: levetiracetam, oxcarbazepine and zonisamide. J Child Neurol. 2002;17:53–7.CrossRef Leppik IE. Three new drugs for epilepsy: levetiracetam, oxcarbazepine and zonisamide. J Child Neurol. 2002;17:53–7.CrossRef
11.
Zurück zum Zitat Schulze-Bonhage A. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010;11:115–26.PubMedCrossRef Schulze-Bonhage A. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010;11:115–26.PubMedCrossRef
12.
Zurück zum Zitat Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure. 1996;5:115–9.PubMedCrossRef Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure. 1996;5:115–9.PubMedCrossRef
13.
Zurück zum Zitat Mula M. Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. Drug Des Dev Ther. 2013;7:397–402.CrossRef Mula M. Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. Drug Des Dev Ther. 2013;7:397–402.CrossRef
14.
Zurück zum Zitat Masuda Y, Ishizaki M, Shimizu M. Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 1998;4:341–60.CrossRef Masuda Y, Ishizaki M, Shimizu M. Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 1998;4:341–60.CrossRef
15.
16.
Zurück zum Zitat Rosler TW, Arias-Carrion O, Hoglinger GU. Zonisamide: aspects in neuroprotection. Exp Neurol. 2010;224:336–9.PubMedCrossRef Rosler TW, Arias-Carrion O, Hoglinger GU. Zonisamide: aspects in neuroprotection. Exp Neurol. 2010;224:336–9.PubMedCrossRef
17.
Zurück zum Zitat Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharamacol. 1998;38:166–71.CrossRef Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharamacol. 1998;38:166–71.CrossRef
18.
Zurück zum Zitat Eisai Pharmaceuticals Inc. Zonegran® (zonisamide) capsules package insert. Eisai Pharmaceuticals Inc; 2006. Eisai Pharmaceuticals Inc. Zonegran® (zonisamide) capsules package insert. Eisai Pharmaceuticals Inc; 2006.
20.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:1–34.CrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:1–34.CrossRef
21.
Zurück zum Zitat Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15:67–73.PubMedCrossRef Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15:67–73.PubMedCrossRef
22.
Zurück zum Zitat Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774–9.PubMedCrossRef Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774–9.PubMedCrossRef
23.
Zurück zum Zitat Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45:610–7.PubMedCrossRef Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45:610–7.PubMedCrossRef
24.
Zurück zum Zitat Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005;46:31–41. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005;46:31–41.
25.
Zurück zum Zitat Lu Y, Zhanqin X, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clin Drug Investig. 2011;31:221–9.PubMedCrossRef Lu Y, Zhanqin X, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clin Drug Investig. 2011;31:221–9.PubMedCrossRef
26.
Zurück zum Zitat Guerrini R, Rosati A, Segieth J, Pellacani S, Bradshaw K, Giorgi L. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54:1473–80.PubMedCrossRef Guerrini R, Rosati A, Segieth J, Pellacani S, Bradshaw K, Giorgi L. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54:1473–80.PubMedCrossRef
27.
Zurück zum Zitat Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11:579–88.PubMedCrossRef Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11:579–88.PubMedCrossRef
28.
Zurück zum Zitat Wroe SJ, Yeates AB, Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand. 2008;118:87–93.PubMedCrossRef Wroe SJ, Yeates AB, Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand. 2008;118:87–93.PubMedCrossRef
29.
Zurück zum Zitat Hasegawa H. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin. 2004;20:577–80.PubMedCrossRef Hasegawa H. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin. 2004;20:577–80.PubMedCrossRef
30.
Zurück zum Zitat Dupont S, Striano S, Trinka E, et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand. 2010;121:141–8.PubMedCrossRef Dupont S, Striano S, Trinka E, et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand. 2010;121:141–8.PubMedCrossRef
31.
Zurück zum Zitat Catarino CB, Bartolini E, Bell GS, Yuen AWC, Duncan JS, Sander JW. The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Res. 2011;96:39–44.PubMedCrossRef Catarino CB, Bartolini E, Bell GS, Yuen AWC, Duncan JS, Sander JW. The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Res. 2011;96:39–44.PubMedCrossRef
32.
Zurück zum Zitat Helmstaedter C, Stefan H, Witt JA. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study. Epileptic Disord. 2011;13:263–76.PubMed Helmstaedter C, Stefan H, Witt JA. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study. Epileptic Disord. 2011;13:263–76.PubMed
33.
Zurück zum Zitat Heo K, Lee BI, Yi SD, et al. Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. Seizure. 2012;21:188–93.PubMedCrossRef Heo K, Lee BI, Yi SD, et al. Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. Seizure. 2012;21:188–93.PubMedCrossRef
34.
Zurück zum Zitat Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol. 2008;12:19–23.PubMedCrossRef Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol. 2008;12:19–23.PubMedCrossRef
35.
Zurück zum Zitat Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open-label, multicenter Italian study. Epilepsy Res. 2009;83:112–6.PubMedCrossRef Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open-label, multicenter Italian study. Epilepsy Res. 2009;83:112–6.PubMedCrossRef
36.
Zurück zum Zitat Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol. 2009;13:3–9.PubMedCrossRef Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol. 2009;13:3–9.PubMedCrossRef
37.
Zurück zum Zitat Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure. 2010;19:31–5.PubMedCrossRef Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure. 2010;19:31–5.PubMedCrossRef
38.
Zurück zum Zitat Mandelbaum DE, Bunch M, Kugler SL, Venkatasubramanian A, Wollack JB. Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy. J Child Neurol. 2005;20:594–7.PubMed Mandelbaum DE, Bunch M, Kugler SL, Venkatasubramanian A, Wollack JB. Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy. J Child Neurol. 2005;20:594–7.PubMed
39.
Zurück zum Zitat Lee YJ, Kang HC, Seo JH, Lee JS, Kim HD. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev. 2010;32:208–12.PubMedCrossRef Lee YJ, Kang HC, Seo JH, Lee JS, Kim HD. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev. 2010;32:208–12.PubMedCrossRef
40.
Zurück zum Zitat Park S, Kim S, Hwang Y, Lee H, Suh C, Kwon S. Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol. 2007;3:175–80.PubMedCentralPubMedCrossRef Park S, Kim S, Hwang Y, Lee H, Suh C, Kwon S. Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol. 2007;3:175–80.PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure. 2004;13:26–32.CrossRef Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure. 2004;13:26–32.CrossRef
42.
Zurück zum Zitat Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Paediatr Neurol. 2006;35:351–4.CrossRef Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Paediatr Neurol. 2006;35:351–4.CrossRef
43.
Zurück zum Zitat Eun S, Kim HD, Eun B, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure. 2011;20:558–63.PubMedCrossRef Eun S, Kim HD, Eun B, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure. 2011;20:558–63.PubMedCrossRef
44.
Zurück zum Zitat Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. J Paediatr Neurol. 2005;32:77–80.CrossRef Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. J Paediatr Neurol. 2005;32:77–80.CrossRef
45.
Zurück zum Zitat Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. Seizure. 2004;13:34–9.CrossRef Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. Seizure. 2004;13:34–9.CrossRef
46.
Zurück zum Zitat Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol. 2005;20:212–9.PubMedCrossRef Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol. 2005;20:212–9.PubMedCrossRef
47.
Zurück zum Zitat Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia. 1985;26:212–20.PubMedCrossRef Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia. 1985;26:212–20.PubMedCrossRef
48.
Zurück zum Zitat Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure. 2004;13:59–65.CrossRef Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure. 2004;13:59–65.CrossRef
49.
Zurück zum Zitat Park S, Hwang Y, Lee H, Suh C, Kwon S, Lee B. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav. 2008;12:102–8.PubMedCrossRef Park S, Hwang Y, Lee H, Suh C, Kwon S, Lee B. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav. 2008;12:102–8.PubMedCrossRef
50.
Zurück zum Zitat Cavanna AE, Ali F, Rickards HE, McCorry D. Behavioural and cognitive effects of anti-epileptic drugs. Discov Med. 2010;9:138–44.PubMed Cavanna AE, Ali F, Rickards HE, McCorry D. Behavioural and cognitive effects of anti-epileptic drugs. Discov Med. 2010;9:138–44.PubMed
52.
Zurück zum Zitat Eddy CM, Rickards H, Cavanna AE. Behavioral adverse effects of antiepileptic drugs in epilepsy. J Clin Psychopharmacol. 2012;32:362–75.PubMedCrossRef Eddy CM, Rickards H, Cavanna AE. Behavioral adverse effects of antiepileptic drugs in epilepsy. J Clin Psychopharmacol. 2012;32:362–75.PubMedCrossRef
53.
Zurück zum Zitat Piedad J, Rickards H, Besag F, Cavanna AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations. CNS Drugs. 2012;26:319–35.PubMedCrossRef Piedad J, Rickards H, Besag F, Cavanna AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations. CNS Drugs. 2012;26:319–35.PubMedCrossRef
54.
Zurück zum Zitat Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. Epilepsy Behav. 2013;29:281–4.PubMedCrossRef Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. Epilepsy Behav. 2013;29:281–4.PubMedCrossRef
55.
Zurück zum Zitat Frampton JE, Scott LJ. Zonisamide—a review of its use in the management of partial seizures in epilepsy. CNS Drugs. 2005;19:347–67.PubMedCrossRef Frampton JE, Scott LJ. Zonisamide—a review of its use in the management of partial seizures in epilepsy. CNS Drugs. 2005;19:347–67.PubMedCrossRef
56.
Zurück zum Zitat Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res. 2006;68:11–6.CrossRef Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res. 2006;68:11–6.CrossRef
57.
Zurück zum Zitat Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res. 2007;75:75–83.PubMedCrossRef Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res. 2007;75:75–83.PubMedCrossRef
58.
Zurück zum Zitat Levy RH, Ragueneau-Majlessi I, Garnett WR, et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004;44:1230–4.PubMedCrossRef Levy RH, Ragueneau-Majlessi I, Garnett WR, et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004;44:1230–4.PubMedCrossRef
59.
Zurück zum Zitat Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet. 2005;44:517–23.PubMedCrossRef Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet. 2005;44:517–23.PubMedCrossRef
60.
Zurück zum Zitat Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit. 2005;27:193–8.PubMedCrossRef Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit. 2005;27:193–8.PubMedCrossRef
61.
Zurück zum Zitat Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther. 2004;26:2056–65.PubMedCrossRef Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther. 2004;26:2056–65.PubMedCrossRef
62.
Zurück zum Zitat Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2005;4:CD001416.PubMed Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2005;4:CD001416.PubMed
63.
Zurück zum Zitat Vossler DG, Conry JA, Murphy JV, ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 2008;10:31–4.PubMed Vossler DG, Conry JA, Murphy JV, ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 2008;10:31–4.PubMed
64.
Zurück zum Zitat Italiano D, Pezzella M, Coppola A, et al. A pilot open-label trial of zonisamide in Unverricht–Lundborg disease. Mov Disord. 2011;26:341–3.PubMedCrossRef Italiano D, Pezzella M, Coppola A, et al. A pilot open-label trial of zonisamide in Unverricht–Lundborg disease. Mov Disord. 2011;26:341–3.PubMedCrossRef
65.
Zurück zum Zitat Kelemen A, Rásonyl G, Neuwirth M, et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz. 2011;64:187–92.PubMed Kelemen A, Rásonyl G, Neuwirth M, et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz. 2011;64:187–92.PubMed
Metadaten
Titel
Zonisamide as a Treatment for Partial Epileptic Seizures: A Systematic Review
verfasst von
Joanna H. Cox
Stefano Seri
Andrea E. Cavanna
Publikationsdatum
01.03.2014
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 3/2014
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-014-0104-1

Weitere Artikel der Ausgabe 3/2014

Advances in Therapy 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.